Larotrectinib
Sign in to save this workspacePrimary targets: TRKA, TRKB, TRKC · FDA status: FDA Approved
Selectivity scorecard
KISS
99.25
Gini
0.710
CATDS
0.047
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Larotrectinib. Strongest target: TRKA at 98.5% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | TRKA | 98.5% | 1.5% |
| 2 | TRKC | 98.1% | 1.9% |
| 3 | TRKB | 97.9% | 2.1% |
| 4 | ROS_ROS1 | 89.5% | 10.5% |
| 5 | ACK1 | 57.8% | 42.2% |
| 6 | MUSK | 52.5% | 47.5% |
| 7 | DDR1 | 51.2% | 48.8% |
| 8 | DDR2 | 43.7% | 56.3% |
| 9 | LIMK1 | 32.8% | 67.2% |
| 10 | TXK | 29.6% | 70.4% |
| 11 | ARK5_NUAK1 | 25.7% | 74.3% |
| 12 | BMX_ETK | 25.3% | 74.7% |
| 13 | TYK1_LTK | 20.5% | 79.5% |
| 14 | JAK2 | 20.3% | 79.7% |
| 15 | GRK6 | 19.2% | 80.8% |
| 16 | MST3_STK24 | 19.0% | 81.0% |
| 17 | MLCK2_MYLK2 | 18.7% | 81.3% |
| 18 | CK2A2 | 18.6% | 81.4% |
| 19 | C_MET | 17.4% | 82.6% |
| 20 | PDK2_PDHK2 | 16.7% | 83.3% |
Selectivity landscape
Where Larotrectinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Larotrectinib.
Atlas insights for Larotrectinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.863 |
| SRR23303752 | — | 0.849 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.846 |
| SRR12202498 | — | 0.838 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.833 |
Annotations
Sign in to read and post annotations.
Loading…